292 related articles for article (PubMed ID: 27072253)
1. Ovarian sertoli-leydig cell tumors: A multicenter long-term clinicopathological analysis of 27 patients.
Akman L; Ertas IE; Gokcu M; Terek MC; Sanci M; Sanli UA; Zekioglu O; Ozsaran AA
J Cancer Res Ther; 2016; 12(1):290-4. PubMed ID: 27072253
[TBL] [Abstract][Full Text] [Related]
2. Sertoli-Leydig cell tumor of the ovary: analysis of a single institution database.
Bhat RA; Lim YK; Chia YN; Yam KL
J Obstet Gynaecol Res; 2013 Jan; 39(1):305-10. PubMed ID: 22691037
[TBL] [Abstract][Full Text] [Related]
3. Results from a Monocentric Long-Term Analysis of 23 Patients with Ovarian Sertoli-Leydig Cell Tumors.
Gouy S; Arfi A; Maulard A; Pautier P; Bentivegna E; Leary A; Chargari C; Genestie C; Morice P
Oncologist; 2019 May; 24(5):702-709. PubMed ID: 30201740
[TBL] [Abstract][Full Text] [Related]
4. A clinicopathological analysis of 40 cases of ovarian Sertoli-Leydig cell tumors.
Gui T; Cao D; Shen K; Yang J; Zhang Y; Yu Q; Wan X; Xiang Y; Xiao Y; Guo L
Gynecol Oncol; 2012 Nov; 127(2):384-9. PubMed ID: 22850410
[TBL] [Abstract][Full Text] [Related]
5. Ovarian Sertoli-Leydig cell tumors. a retrospective MITO study.
Sigismondi C; Gadducci A; Lorusso D; Candiani M; Breda E; Raspagliesi F; Cormio G; Marinaccio M; Mangili G
Gynecol Oncol; 2012 Jun; 125(3):673-6. PubMed ID: 22446621
[TBL] [Abstract][Full Text] [Related]
6. Sertoli-Leydig cell tumor of the ovary: Analysis of a single institution database and review of the literature.
Durmuş Y; Kılıç Ç; Çakır C; Yüksel D; Boran N; Karalök A; Boyraz G; Turan AT
J Obstet Gynaecol Res; 2019 Jul; 45(7):1311-1318. PubMed ID: 31106943
[TBL] [Abstract][Full Text] [Related]
7. Characteristics and outcomes analysis of ovarian Sertoli-Leydig cell tumors (SLCTs): analysis of 15 patients.
Wang G; Zhang R; Li C; Chen A
J Ovarian Res; 2021 Nov; 14(1):150. PubMed ID: 34736487
[TBL] [Abstract][Full Text] [Related]
8. Sertoli-Leydig cell tumor of the ovary.
Chen FY; Sheu BC; Lin MC; Chow SN; Lin HH
J Formos Med Assoc; 2004 May; 103(5):388-91. PubMed ID: 15216408
[TBL] [Abstract][Full Text] [Related]
9. Yolk sac tumours of the ovary: evaluation of clinicopathological features and prognostic factors.
Cicin I; Saip P; Guney N; Eralp Y; Ayan I; Kebudi R; Topuz E
Eur J Obstet Gynecol Reprod Biol; 2009 Oct; 146(2):210-4. PubMed ID: 19419810
[TBL] [Abstract][Full Text] [Related]
10. Treatment of poor-prognosis sex cord-stromal tumors of the ovary with the combination of bleomycin, etoposide, and cisplatin.
Gershenson DM; Morris M; Burke TW; Levenback C; Matthews CM; Wharton JT
Obstet Gynecol; 1996 Apr; 87(4):527-31. PubMed ID: 8602303
[TBL] [Abstract][Full Text] [Related]
11. Outcome and reproductive function after cumulative high-dose combination chemotherapy with bleomycin, etoposide and cisplatin (BEP) for patients with ovarian endodermal sinus tumor.
Kang H; Kim TJ; Kim WY; Choi CH; Lee JW; Kim BG; Bae DS
Gynecol Oncol; 2008 Oct; 111(1):106-10. PubMed ID: 18656249
[TBL] [Abstract][Full Text] [Related]
12. [Clinical analysis of 11 cases of ovarian Setoli-Leydig cell tumor].
Li B; Wu LY; Zhang WH; Li L; Ma SK; Liu LY
Zhonghua Fu Chan Ke Za Zhi; 2004 May; 39(5):334-7. PubMed ID: 15196418
[TBL] [Abstract][Full Text] [Related]
13. Pure Immature Teratoma of the Ovary in Adults: Thirty-Year Experience of a Single Tertiary Care Center.
Alwazzan AB; Popowich S; Dean E; Robinson C; Lotocki R; Altman AD
Int J Gynecol Cancer; 2015 Nov; 25(9):1616-22. PubMed ID: 26332392
[TBL] [Abstract][Full Text] [Related]
14. A phase II study of high-dose cisplatin, vinblastine, bleomycin, and etoposide (PVeBV regimen) in malignant nondysgerminomatous germ-cell tumors of the ovary.
Culine S; Kattan J; Lhomme C; Duvillard P; Michel G; Castaigne D; Leclere J; Pico J; Droz JP
Gynecol Oncol; 1994 Jul; 54(1):47-53. PubMed ID: 7517380
[TBL] [Abstract][Full Text] [Related]
15. Nondysgerminomatous ovarian tumors: clinical characteristics, treatment, and outcome. A case-controlled study.
Ghaemmaghami F; Hasanzadeh M; Karimi Zarchi M; Fallahi A
Int J Surg; 2008 Oct; 6(5):382-6. PubMed ID: 18715834
[TBL] [Abstract][Full Text] [Related]
16. Administration of standard-dose BEP regimen (bleomycin+etoposide+cisplatin) is essential for treatment of ovarian yolk sac tumour.
Satoh T; Aoki Y; Kasamatsu T; Ochiai K; Takano M; Watanabe Y; Kikkawa F; Takeshima N; Hatae M; Yokota H; Saito T; Yaegashi N; Kobayashi H; Baba T; Kodama S; Saito T; Sakuragi N; Sumi T; Kamura T; Yoshikawa H
Eur J Cancer; 2015 Feb; 51(3):340-51. PubMed ID: 25559616
[TBL] [Abstract][Full Text] [Related]
17. Is adjuvant chemotherapy indicated in stage I pure immature ovarian teratoma (IT)? A multicentre Italian trial in ovarian cancer (MITO-9).
Mangili G; Scarfone G; Gadducci A; Sigismondi C; Ferrandina G; Scibilia G; Viganò R; Tateo S; Villa A; Lorusso D
Gynecol Oncol; 2010 Oct; 119(1):48-52. PubMed ID: 20599258
[TBL] [Abstract][Full Text] [Related]
18. Clinicopathologic features of ovarian Sertoli-Leydig cell tumors.
Zhang HY; Zhu JE; Huang W; Zhu J
Int J Clin Exp Pathol; 2014; 7(10):6956-64. PubMed ID: 25400781
[TBL] [Abstract][Full Text] [Related]
19. Ovarian Sertoli-Leydig cell tumor: a report of seven cases and a review of the literature.
Xiao H; Li B; Zuo J; Feng X; Li X; Zhang R; Wu L
Gynecol Endocrinol; 2013 Mar; 29(3):192-5. PubMed ID: 23173550
[TBL] [Abstract][Full Text] [Related]
20. Mucinous adenocarcinoma as heterologous element in intermediately differentiated Sertoli-Leydig cell tumor of the ovary.
Virk R; Lu D
Pathol Res Pract; 2010 Jul; 206(7):489-92. PubMed ID: 19674851
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
